Quantcast

Latest ACRIN Cancer Research Group Stories

2014-07-25 23:01:44

Researchers at the ECOG-ACRIN Cancer Research Group say comprehensive informed consent is likely the key to preventing undue anxiety over lung screenings. Philadelphia, PA (PRWEB) July 25, 2014 A new study of participants in the National Lung Screening Trial (NLST), the results of which are published today in Cancer, found evidence that men and women between the ages of 55 and 74 who had an abnormal finding on a lung cancer screening test did not experience more anxiety or reduced quality...

2014-06-30 23:10:00

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in trial E2112. PHILADELPHIA, Pa. and WALTHAM, Mass. (PRWEB) June 30, 2014 The ECOG-ACRIN Cancer Research Group and Syndax Pharmaceuticals Inc. announced today enrollment of the first patient in E2112, a randomized phase III clinical trial of Syndax’s histone deacetylase (HDAC) inhibitor, entinostat, for the treatment of patients with advanced breast...

2014-03-20 23:22:02

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112. Philadelphia, PA, and Waltham, MA (PRWEB) March 20, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Syndax Pharmaceuticals, Inc., announced today that patient recruitment has begun for E2112, a randomized phase III clinical trial of Syndax’s entinostat in treatment of patients with advanced breast cancer. The...

2014-02-03 23:02:17

Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Philadelphia, PA (PRWEB) February 03, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1912, a randomized phase III clinical trial to evaluate the ability of the combination of ibrutinib and rituximab to prolong progression-free survival in previously...

2014-01-09 23:01:40

Blinatumomab, the first BiTE® antibody to be developed for the treatment of cancer, is being investigated by the ECOG-ACRIN Cancer Research Group in its latest trial, E1910. Philadelphia, PA (PRWEB) January 09, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1910, a randomized phase III clinical trial comparing overall survival after treatment with blinatumomab in combination with chemotherapy vs. chemotherapy alone in adults aged 35 to...

2013-12-13 23:01:59

An analysis by ECOG-ACRIN researchers shows that TILs are a prognostic factor in women with triple negative breast cancer. San Antonio, TX (PRWEB) December 13, 2013 An analysis presented by researchers from the ECOG-ACRIN Cancer Research Group this week at the San Antonio Breast Cancer Symposium showed that stromal tumor-infiltrating lymphocytes (TILs) represent a robust prognostic factor in patients with triple-negative breast cancer (TNBC) who are treated with standard adjuvant...

2013-12-09 23:21:19

Results from an ECOG-ACRIN Cancer Research Group trial show the benefit of using the combination of docetaxel and ADT as initial treatment. Philadelphia, PA (PRWEB) December 09, 2013 Men suffering from highly advanced prostate cancer have new hope for longer survival times based on a recent clinical trial, the interim results of which were just announced by the National Institutes of Health. The findings suggest that physicians can immediately consider changing their clinical practice...

2013-12-09 23:02:27

18 percent of lung cancers detected by low-dose CT are indolent according to ECOG-ACRIN Cancer Research Group study. Philadelphia, PA (PRWEB) December 09, 2013 An analysis of data from the National Lung Screening Trial (NLST), the results of which were published today in JAMA Internal Medicine, suggests that more than 18 percent of lung cancers detected by low-dose computed tomography (LDCT or low-dose CT) may be indolent. “This is another important piece of information that helps us...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin